<DOC>
	<DOCNO>NCT01904279</DOCNO>
	<brief_summary>This open-label , multicenter study evaluate pharmacokinetics , pharmacodynamics safety SC administer TCZ participant pJIA .</brief_summary>
	<brief_title>A Study Subcutaneously ( SC ) Administered Tocilizumab ( TCZ ) Participants With Polyarticular-Course Juvenile Idiopathic Arthritis ( pJIA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>Ages 1 year ( 12 year participant Russia ) include 17 year screen Diagnosis pJIA accord International League Associations Rheumatology classification Rheumatoid factor ( RF ) positive pJIA RFnegative pJIA Extended oligoarticular JIA polyarticular course History inadequate clinical response ( opinion treat physician ) inability tolerate methotrexate ( MTX ) Participants currently receive TCZ intravenous ( IV ) route administration wellcontrolled disease require period discontinuation IV TCZ first dose SC TCZ administer date next IV TCZ infusion would due . Participants participate study may either naive TCZ therapy may switch IV SC . The total number participant switch IV TCZ must account 50 percent ( % ) total participant number . To account baseline TCZ concentration participant , information last 4 IV TCZ infusion prior baseline collect Concurrent treatment diseasemodifying antirheumatic drug ( DMARDs ) ( include MTX ) , nonsteroidal antiinflammatory drug ( NSAIDs ) , oral corticosteroid permit discretion investigator Females childbearing potential nonsterile male female partner childbearing potential must agree use effective contraception define protocol Prior discontinuation IV TCZ inadequate clinical response safety event ( include hypersensitivity ) Participants poorly control disease ( opinion treat physician ) despite current treatment IV TCZ pJIA well control treatment agent TCZ ( Juvenile Arthritis Disease Activity Score 71 [ JADAS71 ] less equal ( &lt; / = ) 3.8 ) Participants wheelchairbound bedridden Any autoimmune , rheumatic disease , overlap syndrome permit pcJIA subset Lack recovery recent surgery interval &lt; 6 week since surgery time screen visit Females pregnant , lactating , intend become pregnant study conduct Any significant concurrent medical surgical condition would jeopardize participant 's safety ability complete study Known human immunodeficiency virus ( HIV ) infection acquire form immune compromise inborn condition characterize compromise immune system History alcohol , drug , chemical abuse within 6 month screen Any active acute , subacute , chronic , recurrent bacterial , viral , systemic fungal infection major episode infection require hospitalization treatment screen treatment IV antibiotic complete within 4 week screen visit oral antibiotic complete within 2 week screen visit History atypical tuberculosis ( TB ) active TB require treatment within 2 year prior screen visit Positive purify protein derivative ( PPD ) screen , unless treat antiTB therapy least 4 week prior receive study drug chest radiograph negative active TB within 6 month screen visit accord local practice History reactivation new onset systemic infection herpes zoster EpsteinBarr virus within 2 month screen visit Hepatitis B surface antigen hepatitis C antibody positivity chronic viral autoimmune hepatitis History concurrent serious gastrointestinal disorder ulcer inflammatory bowel disease , Crohn 's disease , ulcerative colitis , symptomatic low gastrointestinal condition History current cancer lymphoma Uncontrolled diabetes mellitus elevate glycosylated hemoglobin Active uveitis screen Inadequate hematologic , renal liver function Prior stem cell transplant time</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>